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Objective. Current recommendations controversially discuss local infiltration techniques as specific treatment for refractory pain
syndromes. Evidence of effectiveness remains inconclusive and local infiltration series are discussed as a therapeutic option in
patients not responding to standard therapy. *e aim of this study was to investigate the effectiveness of infiltration series with
techniques such as sphenopalatine ganglion (SPG) block and ganglionic local opioid analgesia (GLOA) for the treatment of
neuropathic pain in the head and neck area in a selected patient group. Methods. In a retrospective clinical study, 4960 cases
presenting to our university hospital outpatient pain clinic between 2009 and 2016 were screened. Altogether, 83 patients with
neuropathic pain syndromes receiving local infiltration series were included. Numeric rating scale (NRS) scores before, during,
and after infiltration series, comorbidity, and psychological assessment were evaluated. Results. MaximumNRS before infiltration
series was median 9 (IQR 8–10). During infiltration series, maximum NRS was reduced by mean 3.2 points (SD 3.3, p< 0.001)
equaling a pain reduction of 41.0% (SD 40.4%). With infiltration series, mean pain reduction of at least 30% or 50% NRS was
achieved in 54.2% or 44.6% of cases, respectively. In six percent of patients, increased pain intensity was noted. Initial im-
provement after the first infiltration was strongly associated with overall improvement throughout the series. Conclusion. *is
study suggests a beneficial effect of local infiltration series as a treatment option for refractory neuropathic pain syndromes in the
context of a multimodal approach. *is effect is both significant and clinically relevant and therefore highlights the need for
further randomized controlled trials.
1. Introduction
*e overall prevalence of chronic pain is estimated to be
about 19% in Europe [1, 2]. Worldwide, the estimated
neuropathic pain in the general population is around ten
percent [3]. Particularly, pain in the head and neck area may
be debilitating for patients [4]. Pain syndromes such as
trigeminal neuralgia (TGN) and persistent idiopathic facial
pain (PIFP) often require a multidisciplinary approach
[5, 6]. Management can be challenging as patients some-
times do not respond adequately to noninvasive treatment
[7].*erefore, interventional procedures may be considered,
when pain persists following the completion of conservative
therapy [8, 9].
Feasible techniques in the head and neck area are in-
filtrations at the sphenopalatine ganglion (SPG), the supe-
rior cervical ganglion, the stellate ganglion, and single nerve
blocks of the occipital nerve and branches of the trigeminal
nerve [10, 11].
Since its first description in 1908, the sphenopalatine
ganglion (SPG) block has been discussed in the literature [12].
Recently, an fMRI study showed changes in resting state
functional connectivity after SPG block treatment [13]. *e
literature focuses mostly on SPG block for trigeminal auto-
nomic pain syndromes [14, 15]. Nevertheless, the use in other
pain syndromes such as TGN, PIFP, status migrainosus, and
postdural puncture headache are described as well [8, 16–19].
*e technique appears to be safe and well tolerated [19, 20].
Hindawi
Pain Research and Management
Volume 2020, Article ID 6042941, 10 pages
https://doi.org/10.1155/2020/6042941
Ganglion local opioid analgesia (GLOA) was first in-
troduced by Mays et al. [21], although the term itself de-
veloped later [22]. It describes the infiltration at the superior
cervical ganglion, the stellate ganglion, and sometimes even
the SPG [23–25]. GLOA has been used as a treatment option
for neuropathic and sympathetically mediated pain syn-
dromes of the head, face, and upper extremity [26]. When
using the termGLOA, we refer to infiltrations at the superior
cervical ganglion as defined by Knolle and Kress [27].
Although different indications are discussed, blockade of
the stellate ganglion (SB) is mostly used for Complex Re-
gional Pain Syndrome (CRPS) at the upper extremities [28]
as sympathetic nerves pass through the stellate ganglion
innervating the head, neck, and upper extremities [29]. In
spite of increased evidence for the effectiveness of SB since
the beginning of the 2000s [28], the exact role of the
sympathetic nervous system in both the development of
neuropathic pain and its treatment remains unclear [29, 30].
Peripheral nerve blocks can be helpful in cranial neu-
ralgias such as TGN and glossopharyngeal and occipital
neuralgias [31]. Although evidence from clinical trials for
efficacy and tolerability is inconclusive [7], an infiltration
series as a treatment option for neuropathic pain is used in
clinical practice [32].
*e reason to use an infiltration series and not a single
infiltration is mostly based on historical development of
clinical practice [33]. Until now, there is no evidence-based
recommendation regarding the number and frequency of
infiltrations [33, 34].
Considering this background, this study was performed
to investigate the course of pain and pain relief, the asso-
ciated symptoms, and side effects during the administration
of a local infiltration series in patients with refractory
neuropathic pain of the head and neck region.
2. Materials and Methods
*is retrospective study was conducted at the outpatient
pain center of the Charite´ University Hospital, Berlin,
Campus Virchow-Klinikum. *e department provides
clinical care for chronic pain patients and is run by a team of
pain specialists, psychotherapists, and trained pain nurses.
All cases treated in the department presenting from January
2009 to June 2016 were screened for eligibility. Inclusion
criteria were adult patients receiving local infiltration series
for treatment of refractory neuropathic pain syndromes
(e.g., TGN and trigeminal post-herpetic neuralgia) [35, 36]
or pain syndromes with neuropathic characteristics in the
head and neck area (e.g., PIFP). Exclusion criteria were
missing data files, cases with insufficient documentation,
patients without infiltration series in head and neck area, or a
different type of pain syndrome (e.g., CRPS). Cases fulfilling
the criteria were included for analysis. All infiltration series
were embedded in multimodal therapy concepts following
the current recommendations [37, 38]. *e study was reg-
istered on ClinicalTrials.gov with the identifier
NCT03066037. *e study was approved by the Charite´
Ethical Committee (EA4/107/16).
2.1. Assessment of Pain and the Questionnaires. All patients’
contacts in the department were documented in the elec-
tronic and paper-based patient filing system. For patients
receiving infiltrations, a specific documentation protocol
was used. Protocols contain NRS at rest, under stress, before
and at 1, 6, and 24 hours after infiltration on an 11-point
Likert scale (0–10). A self—assessment of pain reduction and
the infiltration’s burden (1� extreme, 2� severe, 3� little,
and 4� very little) was assessed on a 4-point Likert scale.
Additional to these infiltration protocols, the daily form
of the validated German Pain Questionnaire adopting the
2007 version [39] was used. One question describes average
pain; another question describes maximum pain on an 11-
point Likert scale (0–10). A different question assesses the
endurance of pain on a 4-point scale (1� not applicable, I
have no pain, 2� I can tolerate it well, 3� I can just tolerate
it, and 4� I can tolerate it badly). Two questions focus on
problems regarding the quality of life (QOL) as suggested by
Barker [40]: one examines the impairment in daily activities
such as labor, domestic work, and leisure time on an 11-
point Likert scale (0–10). A further question describes
mental distress on an 11-point Likert scale (0–10).
2.2. 1e Infiltration Technique. Patients were scheduled for
the local infiltration series depending on the clinical
judgement of the attending pain specialists. *e infiltration
series were scheduled for ten consecutive infiltrations within
three weeks, but the final decision for each infiltration was
based on the clinical outcome.
*e SPG blockade is based on an injection with local
anesthetic agents (2-3ml bupivacaine 0.25%) and opioid (0,
03mg buprenorphine) with or without an adjunctive cor-
ticoid close to the ganglion (Figure S1). *e use of bupre-
norphine in peripheral nerve blocks has been shown to
improve analgesia [41]. We used an infrazygomatic ap-
proach based on the standard protocols [11, 42].
To perform a ganglionic local opioid analgesia (GLOA),
lipophilic opioids and local anesthetic agents (5ml 0.5%
bupivacaine and 0.03mg buprenorphine) are injected close
to paravertebral and cervical ganglions (Figure S2). We used
the anterior paratracheal approach at the C6 level to target
the stellate ganglion blockade (Figure S3). Additionally, all
single nerves can be targeted with local anesthetic injections,
for example, the occipital nerves (Figure S4) and the distal
trigeminal nerve branches (Figure S5) [43]. Further details of
the techniques can be found in the supplementary materials
(Figures S1–S5).
2.3. Statistics. All statistical analyses were performed using
SPSS 25 and G∗Power 3.1.9.6 (post hoc power). Descriptive
data was summarized using mean and standard deviation or
median and range depending on scale level and distribution.
For analysis of statistical significance, NRS scores (0–10)
were explored using the exact Wilcoxon signed-rank test for
paired data. To analyze independent groups, the Man-
n–Whitney test was applied. To examine the time point of
successful pain reduction, the Kaplan–Meier analysis was
performed. For analysis of the correlation between the initial
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and the final response to infiltration, an exact Chi-square test
was performed. To analyze differences in percentage of NRS
reduction throughout series by subgroups, the Krus-
kal–Wallis test was performed. For examination of the re-
sponse rate between subgroups, the Fisher exact test was
performed. All statistical significance tests used a two-sided
alpha level of <5% and were intended as exploratory data
analysis.
Like previous studies, we defined nonresponders as
patients with less than 30% pain reduction and responders
as patients with a pain reduction of at least 30% [44]. As
additional analysis, we repeated responder analyses with a
threshold of 50% pain reduction. To analyze factors as-
sociated with responders, we performed univariate and
multivariate logistic regression analyses. Based on uni-
variate regression, factors meaningfully associated with the
clinical response on an alpha level of at least 10% entered
the multivariate regression analysis. *is first step was
entering the variables sex, age, use of corticosteroids
during infiltration, months of preceding pain until the first
infiltration, comedication (opioids, antidepressants, and
antiepileptics), improvement in maximum NRS scores
after the first infiltration, and also improvement in
maximum NRS after the first two infiltrations. To assess
the calibration of regression analysis, the Hos-
mer–Lemeshow test was performed. *e effect size was
examined using Cohen’s f [45].
3. Results and Discussion
In total, 4960 cases that presented to the pain outpatient
center of the Charite´ University Hospital were screened.
Most of these patients did not receive any invasive treat-
ments. For the purpose of this study, patients with refractory
pain in the head and neck area scheduled for the local in-
filtration series between January 2009 and July 2016 were
investigated. We identified 144 patients fulfilling the in-
clusion criteria. After excluding 61 ineligible patients, N� 83
patients were included into further analysis (Figure 1). With
this subgroup of patients, the mean patient age was 60.4
years (SD± 15.7) and 50 patients (60.2%) were females. *e
median time between the onset of pain until the first in-
filtration was 19 months (IQR 4–65).
3.1. Patients’ Conditions. Most patients suffered from either
trigeminal neuralgia, trigeminal postherpetic neuralgia, or
persistent idiopathic facial pain (PIFP) (Table 1). Psychiatric
preexisting conditions were present in 23 patients (27.7%)
and depression was present in 14 patients (16.9%). Patients
were treated with different analgesic and coanalgesic drugs
as given in Table 1.
3.2. 1e Blockade Technique. Most patients received a
blockade at the sphenopalatine ganglion (N� 60, 72.3%) as
the main infiltration site. GLOA infiltration was applied in
N� 12 patients (14.5%) and infiltrations at the stellate
ganglion in N� 6 (7.2%). Other infiltration sites were the
branches of the trigeminal nerve (V1, N� 2 patients, 2.4%;
V2, N� 1, 1.2%) and the major (N� 1, 1.2%) and minor
occipital nerve (N� 1, 1.2%).
3.3. Change in Pain: Short-TermEffectiveness. *emaximum
NRS score leading to the decision to perform the local in-
filtration series was a median of 9 (IQR 8–10, complete data
for N� 81 patients). A mean reduction of maximum NRS
scores during the course of infiltrations was 3.2 (SD± 3.3);
the median was 3 (IQR 0–6; p< 0.001, N� 75 patients). *is
equals a relative average reduction of maximum NRS scores
of 40.9% (SD± 40.4%); the median was 44.4% (IQR 0%–
70%).
A reduction of at least 30% of the initial maximum NRS
compared to the last documented maximum pain was
achieved in 45 patients (54.2%), a 50% reduction in 37
patients (44.6%). Worsening of pain was noted in five pa-
tients (6%). *e mean increase of maximum NRS in these
five patients throughout the series was 1.8 (SD± 0.83).
Numeric rating scale scores during the course of infiltration
are presented in Figure 2. Additionally, inverse
Kaplan–Meier analysis was conducted to visualize the re-
sponse to treatment on a 30%- and 50%-level over time
(Figure 3).
3.4. Burden of the Block Series. During the first infiltration
series, patients commonly tolerated the infiltrations well.












(i) Received no infiltration n = 5
(ii) Different type of pain n = 38
(iii) Missing data file n = 16
(iv) Duplicate n = 2
n = 61
Figure 1: STROBE chart indicating the process of patient re-
cruitment for this retrospective study.
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(46.2%) to very little burden (33%). Severe (16.3%) and
extreme burden (4.4%) were rarely reported.
3.5.Change inPain:Long-TermEffectiveness. For 48 patients,
data from the German Pain Questionnaire was available for a
follow-up time point, which was a median of two months
(IQR 1–3 months) after the infiltration series.
Evaluating the maximum NRS at the beginning of the
infiltration series and the maximum pain ratings at follow-
up time point, there was an improvement over time, though
not formally statistically significant (N� 76, median 8 (IQR
6–9); follow-up N� 44, median 6 (IQR 3.3–8), and p � 0.05)
(Figure S6).
Compared with preinfiltration status, patients reported
statistically significant improvements of endurance of pain
(before median 3 (IQR 3-4); after median 3 (IQR 2-3),
p � 0.023), impact of daily activities (before median 5 (IQR
4–8); after median 4 (IQR 2–7), p � 0.046), and mental
constitution (before median 6 (IQR 5–8); after median 5
(IQR 2.5–7.5), p � 0.002).
3.6. Identification of Responders: Prediction Models.
Responders were defined as patients with maximum NRS
scores decreasing by at least 30% during treatment. *is
analysis was repeated for patients with at least a 50%
response.
In univariate logistic regression models, variables with
potential association with clinical response were included. In
the final model, identified relevant variables predicting re-
sponse were age and relevant improvement in maximum
NRS scores after the first two infiltrations (Table 2). Notably,
the variable with thehighest predictive value was response
after the first infiltration with an OR of 4.833 (95% CI
1.562–14.955). *e same approach was used to address a
pain reduction of at least 50%. Identified variables associated
with a 50% response were age and months with preceding
pain until first infiltration, whereas improvement in maxi-
mum NRS scores after the first two infiltrations showed a
nonsignificant trend (Table 2).
3.7. Subgroup Analysis. To further explore clinical sub-
groups, patients with three dominant pain syndromes in
this study population, trigeminal neuralgia, trigeminal
postherpetic neuralgia, and persistent idiopathic facial pain
(PIFP), were analyzed separately in Table 3.
For patients with trigeminal neuralgia (n� 38), clinically
relevant NRS reduction of 30% was achieved in 22 cases
(51.2%) and a reduction of 50% in 19 cases (44.2%), re-
spectively. In patients with trigeminal postherpetic neuralgia
(n� 13), a reduction of at least 30% of initial maximum NRS
compared to last documented maximum pain was noted in
11 patients (84.6%) and a 50% reduction in eight patients
(61.5%). In the PIFP subgroup (n� 12), a reduction of 30%
NRS throughout series was achieved in 5 cases (35.7%) and a
reduction of 50% in 4 cases (28.6%), respectively. Differences
in response rates both for 30% reduction (p � 0.081) and
50% reduction (p � 0.387) were not statistically significant
(Figure S7).
4. Discussion
*e main findings of this observational study were that (1)
the local infiltration series resulted in a meaningful clinical
Table 1: Basic characteristics for N� 83 patients included with refractory neuropathic pain syndromes in the head-neck area.
Variable N� 83patients
Female gender n (%) 50 (60.2%)
Age in years mean (±SD) 60.4 (±15.7)
Median (25–75 quartile) 57 (51–74)
Duration onset of pain until first infiltration (months) (N� 76), median (quartiles) 19 (4–65)
Medication at the beginning of infiltration series n in %
WHO I: n (%) 20 (24.1%)
WHO II: n (%) 16 (19.3%)
WHO III: n (%) 18 (21.7%)
Coanalgesic drugs:
Antidepressants n (%) 65 (78.3%)
Antiepileptics n (%) 75 (90.4%)
Other
Psychiatric pre-existing condition n (%) 23 (27.7%)
Depressions n (%) 14 (16.9%)
Infiltration with additional corticosteroid n (%) 69 (83.1%)
Neuropathic pain classified following ICHD 3 [46], given in n (%)
Headache or facial pain attributed to other disorders of cranium, neck, eyes, ears, nose, sinuses, teeth, mouth, or other
facial or cervical structure, 11.9 5 (6%)
Trigeminal neuralgia, 13.1 43 (51.8%)
Trigeminal postherpetic neuralgia, 13.1.2.2 13 (15.7%)
Persistent idiopathic facial pain (PIFP), 13.12 14 (16.9%)
Others 8 (9.6%)
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Figure 2: NRS indication, NRS beginning and ending, and NRS during the course of infiltration. (a) A boxplot showing the NRS score for
the indication of infiltration series. N� 81, mean� 8.65 (SD± 1.61), and median� 9 (IQR 8,10). (b) Two boxplots comparing the NRS score
for maximum pain before the first infiltration and at the ending of infiltration series. A significant NRS reduction was achieved, p< 0.001. (c)
*is graphic shows the NRS scores during the infiltration series until data from at least 50% of initially treated patients was available.
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Infiltration of infiltration series
6.00 8.00
Inverse Kaplan-Meier analysis with events defined as 50% NRS reduction
(b)
Figure 3: Inverse Kaplan–Meier analysis. (a) Inverse Kaplan–Meier curve with events defined as accomplishment of 30% reduction of initial
NRS score. N� 83; event N� 55 (66.3%). (b) Inverse Kaplan–Meier curve with events defined as accomplishment of 50% reduction of the
initial NRS score. N� 83; event N� 49 (59%).
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pain reduction of 30% in notably 54% of patients (and 50%
pain reduction in 45% of patients); (2) the follow-up patients
reported a lasting reduction of pain NRS, along with (3)
improvements in pain-related psychometrics. Finally, we
were able to identify the variables age, months with pre-
ceding pain until the first visit at the outpatient pain center,
and improvement in pain NRS scores after the first two
infiltrations as predicting factors for clinical response of
infiltration series.
Although facial pain is a rare condition with an overall
incidence rate of 38.7 per 100,000 patient years, it can have a
considerable impact on the patients’ quality of life [47].
Refractory pain syndromes are especially difficult to treat
and often require a multidisciplinary approach [5], which
may include interventional procedures [4, 8].
In patients with neuropathic pain who fail to respond
adequately to pharmacological management, the consideration
of nonpharmacological therapies is recommended [48]. In-
vasive treatments are thought to be part of a more compre-
hensive approach including pharmacological and
nonpharmacological, noninterventional treatments [7]. In-
terventions like infiltrations could alleviate pain in conditions
such as TN [49]. *erefore, it is possible to bridge the time gap
until long-lasting multimodal treatment can be effective.
*ere are different approaches to access the sphenopa-
latine ganglion. Blocks at the sphenopalatine ganglion have
been both used with regional placement of local anesthetic
through the nose either via soaked cotton tips [12, 50] or
placement tools [51] or via different approaches for injec-
tions. Ruskin favors the transoral approach [52, 53], while
Devoghel points out the risk of this pathway and prefers the
suprazygomatic way [14]. We used the infrazygomatic ap-
proach, which is easy to target and appears to be safe. A
recent imaging study questions whether the local anesthetic
drug reaches its goal in the widely used transnasal approach
[54]. Due to its effect on the parasympathetic, sympathetic,
and sensory nervous system [50] and because of its ana-
tomical connections and role in the trigeminoautonomic
reflex [20], the SPG has been the focus of physicians treating
pain in the head and neck area. It seems to be important in
pain syndromes such as TN, PIFP, and herpes infections [19]
and is used for the treatment of status migrainosus [18].
Although employed for various pain syndromes, most of the
studies regarding SPG are anecdotal and remain contro-
versial [19].
Regarding GLOA, a previous study shows that its
treatment had an adjunctive beneficial effect in carbamaz-
epine-treated patients with trigeminal neuralgia [55]. In a
placebo-controlled double-blind study with 14 patients,
Spacek et al. found significant lower NRS values after
crossover to the nonplacebo group [56]. Elsner et al. showed
a similar beneficial effect of GLOA in a comparable patient
Table 3: Pain reduction for study subgroups. Absolute NRS reduction did not differ statistically between groups (p � 0.276).
Number of patients Mean NRS reduction (SD) Median NRS reduction (IQR) p
Trigeminal neuralgia 38 3.5 (±3.2) 3.5 (0–6.25) <0.001
Trigeminal postherpetic neuralgia 13 3.6 (±1.8) 3.0 (2–5) �0.001
PIFP 13 1.6 (±4.3) 0 (0–5) �0.159
Table 2: Logistic regression analyses.
Univariate regression analysis Multivariate regression analysis
OR (95% SD) p OR (95% SD) p
A
Female sex 0.684 (0.261–1.791) 0.440
Corticoid use during infiltration 1.156 (0.357–3.750) 0.809
Age 1.045 (1.012–1.080) 0.007 1.052 (1.009–1.098) 0.018
Months in pain until the first visit 1.004 (0.996–1.011) 0.347
Cotherapy opioids 0.552 (0.215–1.413) 0.215
Cotherapy antidepressants 1.000 (0.315–3.174) >0.999
Cotherapy antiepileptics 1.000 (0.157–6.373) >0.999
Improvement after the first infiltration 4.833 (1.562–14.955) 0.006
Improvement after the first two infiltrations 8.017 (2.431–26.436) 0.001 7.484 (2.089–26.816) 0.002
B
Female sex 0.682 (0.268–1.737) 0.423
Corticoid use during infiltration 1.378 (0.427–4.46) 0.592
Age 1.034 (1.004–1.066) 0.029 1.061 (1.016–1.108) 0.008
Months in pain until the first visit 1.007 (0.999–1.015) 0.079 1.011 (1.011–1.021) 0.024
Cotherapy opioids 0.602 (0.238–1.522) 0.284
Cotherapy antidepressants 0.819 (0.263–2.543) 0.729
Cotherapy antiepileptics 0.630 (0.099–4.003) 0.624
Improvement after the first infiltration 2.413 (0.858–6.781) 0.095
Improvement after the first two infiltrations 3.491 (1.125–10.829) 0.030 3.579 (0.898–14.255) 0.071
Univariate and multivariate logistic regression analyses were used to predict a clinical response of at least 30% (A) and a pain reduction of 50% (B) as
dependent variable. Multivariate analysis was performed with variables of at least p � 0.1 in univariate testing. Hosmer–Lemeshow goodness-of-fit test was
sufficiently for multivariate regression model (A: Chi2 12.056, p � 0.099; N� 66; B: Chi2 8.763, p � 0.363; N� 61).
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group [44]. *e superior cervical ganglion, which is targeted
by the GLOA, is part of the cervical sympathetic trunk [57]
and consequently part of the sympathetic nervous system
(SNS) [58].
As there is no communication between autonomic
postganglionic sympathetic and parasympathetic neurons
with afferent neurons under physiological conditions [59],
the role of the SNS in pain is under debate. Nevertheless,
under pathophysiological conditions, sympathetic post-
ganglionic neurons may be involved in the generation of
pain [59, 60]. It is believed that there is a connection between
the SNS and painful peripheral neuropathy [61, 62].*e SNS
might regulate neuroactive molecules, immune cells, and
peripheral sensitized nociceptors and therefore have an
influence on pain modulation [63]. Hence, sympathetically
maintained pain could be treated with nerve blocks of the
SNS like GLOA [64].
*e SNS is targeted in the SB as well: sympathetic nerves
passing through the stellate ganglion innervate the head,
neck, and upper extremities [29] and its blocks are used in
cases of facial pain. *eories of its mechanism involve relief
of vascular spasms by blocking sympathetic fibers and thus
increasing the blood supply of the brain [29, 65]. Another
theory is based on the blocks’ sedative effect [66].
*e block of the greater occipital nerve (GON) is thought
to be an effective treatment for acute migraine [67]. Fur-
thermore, a recent case report describes its use in a patient
presenting with persistent headaches following accidental
dural puncture [68].
To compare different therapy options, a definition of
successful treatment is needed. Although widely used, a
definition of the success of nerve blocks is still not
established. Generally, a relevant NRS reduction of 30% of
initial NRS represents a clinically important difference [69].
Elsner et al. defined an NRS reduction of 30% as satisfying,
50% as good, and 70% as very good [44]. In a survey,
German pain therapists estimated that 55% of patients
treated in a pain center achieve a successful reduction of
pain intensity [32].
Subgroup analyses of the major clinical entities included
trigeminal neuralgia, postherpetic neuralgia, and persistent
idiopathic facial pain (PIFP). We observed a nonsignificant
difference between the response rates to treatment. How-
ever, for the limited subgroup of PIFP patients, treatment
benefit appeared numerically smaller. In contrast, patients
with trigeminal neuralgia and trigeminal postherpetic
neuralgia were comparable in terms of treatment response,
which may be of relevance in planning prospective trials.
Repetitive blocks are frequently used [32]. One reason is
this intention to break the pain cycle by effecting a mod-
ulation of autonomic pathways [70]. *ere is no established
number of infiltrations during the series. Repetitions with 3,
6, or 10 infiltrations per series are common [32]; recent study
protocols use up to 12 repetitions [51, 71].
Our results show an overall improvement over the first 6
infiltrations. Together with our clinical experience, we
recommend at least 6 scheduled infiltrations in a context-
sensitive treatment. Notably, our results show that an im-
provement of NRS in the first and even stronger
improvement in the first two infiltrations have a significant
predictive value on clinical response. *erefore, the first two
infiltrations could be used to identify patients with a higher
likelihood to benefit from the treatment. *is is relevant
since it could prevent performing unnecessary interventions
in patients who are unlikely to improve.
Invasive procedures as investigated in this study have
enhanced placebo effects [72, 73]. Particularly, physical
placebo interventions and patient-involved outcomes such
as NRS can especially show the effects of placebo inter-
ventions [74]. In a systematic review of migraine prophy-
laxis, Meissner et al. discussed that more invasive placebo
treatments had a stronger effect than less invasive ones. A
stronger reduction of migraine frequency was found in sham
acupuncture (proportion of responders, 0.38 [95% CI,
0.30–0.47]) and sham surgery (0.58 [0.37–0.77]) than in oral
pharmacological placebos (0.22 [0.17–0.28]) [75].
Nevertheless, the effect of placebo interventions on pain
is very variable. Hrobjartsson and Gotzsche identified seven
placebo interventions on pain trials which were divided into
two subgroups: four German acupuncture trials with a
pooled effect of standardized mean difference (SMD) −0.68
(−0.85 to −0.50) and three other trials with an effect of SMD
−0.13 (−0.28 to 0.03), which equals an effect on pain on a
100mm visual analogue scale of 16mm and 3mm, re-
spectively. *us, the placebo effect on reported pain ranges
from clinically important to irrelevant [74].
In our study, we could show a significant and clinically
relevant reduction of NRS. *is goes along with findings
from a similar study about GLOA as a local infiltration
technique [44]. Furthermore, we could detect an improve-
ment in important psychosocial scores such as the impact on
daily activities and patient’s mental constitution. *is is
relevant, since neuropathic pain is associated with important
impairments of a broad spectrum of health-related quality-
of-life domains [76–78].
4.1. Limitations. However, this study has limitations. *e
retrospective design limits the interpretation of the results.
Furthermore, it is not possible to distinguish between the
effects of blocks, the placebo effect, other treatments and the
natural course of pain syndromes. In addition, there could
be a selection bias regarding the follow-up group, since
patients without pain are more likely not to visit our out-
patient pain clinic. Moreover, the subgroup of patients with
PIFP could have a lower response rate to treatment and thus
estimated that the overall study response rates could be
underestimated in their assessment. Additionally, there is
very limited literature regarding head and neck nerve blocks
and no standardization of its performance [43]. Particularly,
the techniques used for SPG block and GLOA vary widely
between different authors.
In this investigation with repetitive data collections, we
could not control for all factors, e.g., intraindividual variance
of patients. For example, for plain NRS reduction of 3.2
points in pain intensity over the course of treatment, we
achieved a power of 99.9% (p � 0.001), which does suggest a
low probability of bias regarding the intraindividual
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variation. *e latter may also be an important piece of in-
formation in designing prospective trials. Although there are
potent correction methods for multiple comparisons, this
study is exploratory with a nonconfirmatory design. In such
studies, conservative procedures like Bonferroni’s correction
may further increase the risk of type 2 errors [79].
4.2. Clinical Significance. Local infiltration series are used in
patients with refractory neuropathic pain syndromes despite
lacking evidence. Our study provides data on effectiveness
and the burden of local infiltration techniques in patients not
responding to standard therapy. *is is important, since
randomized—controlled trials are ethically difficult to per-
form in invasive procedures. Furthermore, we have evalu-
ated factors to predict response to therapy to guide
patient—management during the infiltration series.
5. Conclusions
In summary, this retrospective analysis demonstrates a
beneficial effect of local infiltration techniques as a treatment
option for refractory pain syndromes. *e effects of the
treatment with the infiltration series are significant and
appear clinically relevant as therapeutic options are limited
in this population [48, 80]. Further studies with prospective,
controlled design and long-term data are necessary to val-
idate these findings.
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